Gevel Trio 1 Tablet ER is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Voglibose 0.3mg, formulated for extended-release administration. This fixed-dose combination is indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, minimizing postprandial hyperglycemia. The extended-release formulation allows for sustained plasma drug levels, potentially improving glycemic control and patient compliance by reducing dosing frequency. Gevel Trio 1 Tablet ER should be used as part of a comprehensive diabetes management plan including diet and exercise. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. Potential adverse effects include hypoglycemia, gastrointestinal disturbances, and lactic acidosis. This combination therapy offers a multifaceted approach to glycemic control by targeting different pathophysiological mechanisms of type 2 diabetes.